ClinicalTrials.gg

Program

Bupivacaine

Also written as “HTX-011”, “SKY0402” and “Bupivacaine HCl”.

Its studies are mostly in Pain, Postoperative · Pain · Hernia, Inguinal · Bunion · Hemorrhoids, led by 10 companies.

Furthest: phase 4, since Oct 24, 201156 company-led studies, 4 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pacira BioSciences230 open or runningphase 4since Oct 24, 2011Jun 11, 2007none ahead
Heron Therapeutics171 open or runningphase 4since Oct 10, 2018Jun 9, 2015none ahead
Innocoll60 open or runningphase 3since Aug 12, 2015Oct 18, 2010none ahead
Bausch Health Companies20 open or runningphase 3since Oct 9, 2015Mar 30, 2010none ahead
Cristália Produtos Químicos Farmacêuticos Ltda.20 open or runningphase 3since Feb 23, 2011Feb 23, 2011none ahead
Jiangsu HengRui Medicine22 open or runningphase 4since Mar 13, 2024Mar 13, 2024Nov 2026phase 2 · NCT06529432
Ascension Health10 open or runningphase 3since Nov 20, 2019Nov 20, 2019none ahead
liquidia-technologies-inc10 open or runningphase 1since Nov 22, 2016Nov 22, 2016none ahead
Rebel Medicine11 open or runningphase 2since Apr 28, 2026Apr 28, 2026none ahead
Tian Medical10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: Pfizer, premier-research-group-plc and richmond-pharmacology-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 41 studies since Jun 11, 2007.

  1. Apr 17, 2019Phase 2 study in AgnosiaHeron Therapeutics · NCT03922048
  2. May 9, 2019Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT03955211 · 25 enrolled · United States
  3. Jun 3, 2019Phase 3 study in AgnosiaHeron Therapeutics · NCT03974932 · 116 enrolled · United States
  4. Jun 25, 2019Phase 1 study in BunionPacira BioSciences · NCT04002089 · 45 enrolled · United States
  5. Nov 20, 2019Ascension Health's first study: phase 3 study in AgnosiaNew to Ascension HealthAscension Health · NCT04173312 · 120 enrolled · United States
  6. Aug 4, 2020Phase 3 study in BunionPacira BioSciences · NCT04518462 · 121 enrolled · United States
  7. Mar 1, 20212 phase 3 studies in Pain, PostoperativeInnocoll · NCT04785638, NCT04785625
  8. May 27, 2021Phase 2 study in Pain, PostoperativeHeron Therapeutics · NCT04911062 · 32 enrolled · United States
  9. Oct 1, 2021Phase 4 study in AgnosiaHeron Therapeutics · NCT05109312 · 90 enrolled · United States
  10. Oct 25, 20232 phase 4 studies in Pain, PostoperativeHeron Therapeutics · NCT06109428, NCT06109415
  11. Mar 13, 2024Jiangsu HengRui Medicine's first study: phase 4 study in Local Analgesia Via InfiltrationNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06344091 · 232 planned · China
  12. Jul 26, 2024Phase 2 study in Local Analgesia Via Nerve BlockJiangsu HengRui Medicine · NCT06529432 · 96 planned · China
  13. Apr 28, 2026Rebel Medicine's first study: phase 2 study in Hallux ValgusNew to Rebel MedicineRebel Medicine · NCT07574385 · 60 planned · United States
  14. Sep 28, 2026Primary completion moved from 2026-09-28 to 2027-05Date moved laterphase 4 · +8 months · NCT06344091

Ahead

  1. Nov 2026Primary completion: phase 2 study in Local Analgesia Via Nerve BlockJiangsu HengRui Medicine · NCT06529432
  2. May 2027Primary completion: phase 4 study in Local Analgesia Via InfiltrationJiangsu HengRui Medicine · NCT06344091

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 56 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07574385Hallux Valgus · United States2RecruitingRebel MedicineAug 202660
NCT06529432Local Analgesia Via Nerve Block · China2RecruitingJiangsu HengRui MedicineNov 202696
NCT06344091Local Analgesia Via Infiltration · China4RecruitingJiangsu HengRui MedicineMay 2027232
NCT06109428Pain, Postoperative · United States4CompletedHeron TherapeuticsMar 29, 202237
NCT06109415Pain, Postoperative · United States4CompletedHeron TherapeuticsJul 18, 202230
NCT05109312Agnosia · United States4Active, not recruitingHeron TherapeuticsJun 202490
NCT04911062Pain, Postoperative · United States2CompletedHeron TherapeuticsJul 29, 202232
NCT04785638Pain, Postoperative · United States3CompletedInnocollJan 10, 2023100
NCT04785625Pain, Postoperative · United States3CompletedInnocollOct 27, 2021366
NCT04518462Bunion · United States3CompletedPacira BioSciencesApr 5, 2021121
NCT04173312Agnosia · United States3UNKNOWNAscension HealthJan 2023120
NCT04002089Bunion · United States1CompletedPacira BioSciencesDec 2, 201945
NCT03974932Agnosia · United States3CompletedHeron TherapeuticsDec 7, 2020116
NCT03955211Pain, Postoperative · United States2CompletedHeron TherapeuticsDec 3, 202125
NCT03922048Agnosia2WithdrawnHeron TherapeuticsNov 20250
NCT03907176Agnosia · United States3CompletedHeron TherapeuticsOct 25, 2021209
NCT03718039Pain, Postoperative · United States2CompletedHeron TherapeuticsJan 31, 201978
NCT03705065Pain, Postoperative · United States4CompletedHeron TherapeuticsOct 8, 201830
NCT03695367Pain, Postoperative · United States2CompletedHeron TherapeuticsNov 20, 201863
NCT03295721Pain, Postoperative · United States3CompletedHeron TherapeuticsJan 8, 2018412
NCT03262688Hernia, Inguinal · United States3UNKNOWNInnocollJan 31, 2024159
NCT03237481Pain, Postoperative · United States, Belgium3CompletedHeron TherapeuticsDec 22, 2017418
NCT03015532Pain, Postoperative · United States2CompletedHeron TherapeuticsApr 20, 2018285
NCT03011333Pain, Postoperative · United States2CompletedHeron TherapeuticsFeb 1, 2018243
NCT02982889Acute Pain · Denmark1Completedliquidia-technologies-incMar 23, 201729
NCT02713490Pain · United States4CompletedPacira BioSciencesFeb 8, 2017140
NCT02574520Pain, Postoperative · United States3CompletedBausch Health CompaniesJun 2017399
NCT02525133Pain, Postoperative · United States3CompletedInnocollApr 22, 2016319
NCT02523599Pain, Postoperative · United States3CompletedInnocollApr 2016305
NCT02517905Toothache · United States3CompletedPacira BioSciencesJan 2016166
NCT02504580Pain, Postoperative · United States2CompletedHeron TherapeuticsMar 2017463
NCT02471898Agnosia · United States2CompletedHeron TherapeuticsSep 201571
NCT02284386Pain · United States4CompletedPacira BioSciencesMar 201515
NCT02255500Pain · United States4CompletedPacira BioSciencesMar 201523
NCT02142829Obesity · United States4CompletedPacira BioSciencesMar 2013101
NCT01709708Migraine Disorders · United States4CompletedTian MedicalFeb 201441
NCT01507220Intestinal Obstruction · United States4TerminatedPacira BioSciencesJul 20122
NCT01308047Fracture of Lower Limb · Brazil3WithdrawnCristália Produtos Químicos Farmacêuticos Ltda.0
NCT01303107Cesarean Delivery · Brazil3WithdrawnCristália Produtos Químicos Farmacêuticos Ltda.0
NCT01224145Hernia · United States2CompletedInnocollJun 20, 201110
NCT01206608Pain, Postoperative · United States2CompletedPacira BioSciencesAug 200840
NCT01206595Pain, Postoperative2CompletedPacira BioSciencesMar 200658
NCT01203644Hernia, Inguinal2CompletedPacira BioSciencesJan 200676
NCT01096966Chronic Low Back Pain · United States2CompletedBausch Health CompaniesFeb 2011263
NCT00890721Hemorrhoids · Poland3CompletedPacira BioSciencesNov 2009189
NCT00890682Bunion · United States3CompletedPacira BioSciencesNov 2009193
NCT00813111Pain · United States3TerminatedPacira BioSciencesFeb 2009136
NCT00812305Pain · Poland1CompletedPacira BioSciencesAug 200916
NCT00807209Pain, Postoperative · United States2TerminatedPacira BioSciencesFeb 20093
NCT00806806Agnosia · United States1CompletedPacira BioSciencesFeb 2009128
NCT00745290Pain, Postoperative · United States3CompletedPacira BioSciencesJan 2009245
NCT00744848Hemorrhoids · United States3CompletedPacira BioSciencesFeb 2009204
NCT00529126Pain, Postoperative · United States, Georgia2CompletedPacira BioSciencesDec 2007100
NCT00485693Pain, Postoperative · United States, Czechia2CompletedPacira BioSciencesAug 2009138
NCT00485667Pain, Postoperative · United Kingdom1CompletedPacira BioSciencesAug 200748
NCT00485433Pain, Postoperative · United States2CompletedPacira BioSciencesDec 200798

How it is read

Names in the registry

  • “HTX-011”, 20 entries
  • “SKY0402”, 12 entries
  • “Bupivacaine HCl”, 7 entries
  • “Bupivacaine”, 5 entries
  • “Bupivacaine Liposome Injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.